GERON CORP Non Peo Neo Avg Comp Actually Paid Amt
GERON CORP (GERN) reported Non Peo Neo Avg Comp Actually Paid Amt of -$1.11 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-07.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-07
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | -$1.11M DEF 14A · filed 2026-04-07 |
| 2024-12-31 | $5.94M DEF 14A · filed 2026-04-07 |
| 2023-12-31 | $2.35M DEF 14A · filed 2026-04-07 |
| 2022-12-31 | $2.48M DEF 14A · filed 2026-04-07 |
| 2021-12-31 | $832.84K DEF 14A · filed 2026-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |